INTRODUTION: The oral epidermal growth factor receptor (EGFR) tyrosine-kinase inibitor (TKI) erlotinib is an established second-line treatment for advanced non-small-cell lung cancer (NSCLC).1 Erlotinib delays disease progression and increases survival after first-line chemotherapy in patients with advanced NSCLC as second-line therapy.2 Maintenance therapy with erlotinib, when compared to placebo, could be ass...
Financiadores do RCAAP | |||||||
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |